Summary: Clinical Trials Arena reports on the long-term follow-up results compiled from six trials of MDMA-assisted psychotherapy for PTSD, which demonstrated continued improvement in most patients for more than one year after the treatment ended. The long-term data shows 67% of participants no longer met diagnostic criteria for PTSD after one year, compared to 56% of participants at the original endpoint of the trials. These results further add to previous data on the potential effectiveness of the treatment and “makes it one of the most promising agents in the pipeline for PTSD,” says Clinical Trials Arena.
Originally appearing here.
